N/A N=120 Clearblue Home Pregnancy Test Consumer Study
Pregnancy
Primary: Consumer Agreement — 100 percentage of agreement
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=12 Pharmacokinetics of NPC-01 After Single Oral Administration in Healthy Female Volunteers
Healthy
Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) on Norethisterone of NPC-01 — 69.183 ng･hr/mL
Phase 1 N=10 Quantification of Estradiol's Impact on Nucleotides in Cellular Populations of the Lower GI Tract
HIV/AIDS
Primary: Average Tenofovir Diphosphate Concentrations in Mixed Rectal Cells During the Early (Low Estradiol) Follicular Phases of the Menstrual Cycle. — 406.14 fmol/million cells
Phase 2 N=96 Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities
Healthy · Pituitary Disease · Thyroid Disease
Primary: TSH Response to TRH — 11.47 mcIU/mL
Phase 1 N=23 A Study to Learn How Different Amounts of the Study Medicine Called PF-06954522 Are Tolerated and Act in the Body in Healthy Adults
Healthy Participants
Primary: Cohort 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 5; 8; 6; 8 Participants
N/A N=12 Uroflow Measurements in Healthy Volunteers
Healthy
Primary: Voided Volume — 306 mL
Phase 1 N=23 A Study to Learn About the Study Medicine PF-07853578 and How it Acts in the Bodies of Healthy Adults
Healthy Participants
Primary: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) — 1; 2; 3; 2 Participants
Phase 1 N=82 A Study of LY3484356 in Healthy Female Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3484356 (Cohort 1) — 1810; 4350 nanogram*hour per milliliter…
Phase 1 N=41 A Study of OsrHSA in Adult Healthy Male and Female Volunteers
Ascites Hepatic
Primary: Incidence of Treatment-Emergent Adverse Events — 1; 0; 2; 1 Participants
Phase 1 N=34 Bioequivalence Trial of Liquid Versus Freeze-Dried Pergoveris® in Pituitary Suppressed Healthy Premenopausal Female Subjects
Healthy
Primary: Baseline Corrected Area Under the Concentration-Time Curve From Zero to Last Quantifiable Concentration (AUC 0-t,Adj) for Follicle-Stimulating Hormone (FSH) — 3187.4…
N/A N=37 Pilot Investigation of a Multinutrient Supplement on Skin Aging and Aging Metabolites in Healthy Women
Skin Diseases
Primary: Fold Change in Long Chain Fatty Acids — 1; 0.76 Fold Change in long chain fatty acids
N/A N=200 Urinalysis Results in Healthy Individuals
Asymptomatic Bacteriuria · Asymptomatic Pyuria
Primary: False Positive Urine — 6; 40 Participants
Phase 1 N=24 Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy Volunteers
Healthy Volunteers
Primary: Maximum Observed Concentration in Plasma (Cmax) of Pexidartinib — 4580; 7090; 3870 ng/mL
Early Phase 1 N=43 Brain Imaging of Cannabinoid Receptors
Cannabis Use Disorder · Cannabis Dependence, Continuous
Primary: Distribution Volume (VT) — 1.27; 1.54; 1.14; 1.31 mL/cm^3 — p=0.02
N/A N=49 Feasibility Study for Development of an Early Test for Ovarian Failure
Healthy · Premature Ovarian Failure
Primary: Follicle Stimulating Hormone Stimulated Serum Inhibin B Levels. — 50.7; 48.8; 96.6; 47.7 participants
Phase 1 N=26 Study of Serum Testosterone and Nestorone in Females After Secondary Exposure to Nestorone ® (NES) + Testosterone (T) Combined Gel Applied to Shoulders and Upper Arms in Males
Healthy Men · Male Contraception · Healthy Women
Primary: Changes From Baseline (Cavg) for Serum Testosterone Levels in Females After Secondary Exposure to Nestorone + Testosterone Combination Gel — 22.84; 27.12; 29.12; 62.06…
N/A N=5 Urinary Proanthocyanidin-A2 as a Biomarker of Compliance to Intake of Cranberry Products
Urinary Tract Infection
Primary: Proanthocyanidin A2 — 0.6; 0.20 ng/mg creatinine
Phase 1 N=24 A Study to Learn About the Study Medicine (PF-07293893) at Different Dose Levels in Healthy Adults
Healthy Participants
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 1; 2; 1; 2 Participants
N/A N=159 Testing and Calibration of Non-Invasive Optical Imaging Technology for Functional Brain Imaging
Cognition
Primary: Relationship Between Prefrontal Cortex Activation and Respiratory Sinus Arrhythmia — -0.064; 0.00375 Micro mol per second — p=0.008
Phase 3 N=14 Pharmacodynamics of NPC-01/IKH-01; Effect of NPC-01/IKH-01 on Sexual Hormone Concentrations in Healthy Female Volunteers
Healthy
Primary: Comparing Estradiol AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA)…
Phase 1 N=5 Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants
Healthy
Primary: The Mean (SD) Amount of [14C] Recovered in Urine, as a Percent of the Total [14C] Dose Administered — 25.2 percentage of dose
Phase 1 N=18 A Study to Evaluate the Pharmacokinetics of Oral Formulations of MMV390048 Administered Fasted to Healthy Volunteers
Malaria
Primary: Cmax: Peak Plasma Concentration — 277; 373.4444 ng/mL
Phase 2 N=21 Study of DARE-HRT1 Over 12 Weeks in Healthy PostMenopausal Women
Vulvovaginal Atrophy · Vasomotor Symptoms
Primary: Number of Participants With Treatment Emergent Adverse Events — 11; 10 Participants
Phase 1 N=62 Phase 1 Study of ELX-02 in Healthy Adult Subjects
Genetic Disease · Nonsense Mutation
Primary: Pharmacokinetic Parameters - Plasma AUC0-24 — 1105.126; 3125.484; 11018.22; 28235.823 ng*h/mL
Phase 4 N=11 PK Sampling After IV Oxytocin and Effects on Sensory Function in Healthy Volunteers
Chronic Pain
Primary: Oxytocin Concentration — 1047 pg/ml
Phase 2 N=25 Positron-Emission Tomography With Vesicular Monoamine Transporter Ligand ([18F]-DTBZ) In Healthy Elderly And Young Subjects
Healthy
Primary: Age-Dependent Change in Striatal 18F-DTBZ Uptake of Healthy Subjects. — 0.05 SUVR
Phase 1 N=48 Phase I Study of Ascending Doses of MMV390048 in Healthy Adult Volunteers
Malaria
Primary: Number of Participants With Adverse Events — 4; 5; 5; 6 Participants
Phase 1 N=12 A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults
Healthy Participants
Primary: Percentage of Total Radiocarbon (14C) Excreted in Urine — 11.9; 20.7 Percentage of 14C in urine
Phase 1 N=12 A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin
Pharmacokinetics · Healthy Volunteers
Primary: Area Under the Concentration-Time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of Rosuvastatin in Period 1 and 2 — 58.62; 72.78 Nanogram*hour per milliliter
Phase 1 N=112 A SAD/MAD Study of Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Volunteers
Cerebrovascular Stroke · Large-Artery Atherosclerosis (Embolus/Thrombosis) · Intracranial Arteriosclerosis
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0; 1; 0; 1 Participants